In: NEOPLASMA, vol. 52, no. 2
L. Miszczyk - G. Wozniak - R. Tarnawski - B. Maciejewski
Detaily:
Rok, strany: 2005, 143 - 149
O článku:
The purpose of the study was to evaluate toxicity and
effectiveness of the split course, accelerated hyperfractionation
with a planned gap (CHA-CHA) on a base of the pilot group
treatment results.
The material consisted of 27 patients with advanced (T2N2c-3, T3-4N2), oral cavity, oro- hypopharynx and larynx cancers,
irradiated with a df 1.6 Gy twice a day, with 6-hour gap, up to TD
64 Gy in 28 days, with 8-day gap in a middle. Mean tumor
dimensions were 4.2 and 3.9 cm in X and Y axes, respectively and
mean nodes dimensions 3.9 cm in both axes. The course and
intensity of the mucositis were evaluated in the Dische scale
together with the degree of a tumor and nodes regression. Survival
analysis and dependencies evaluation between physical/biological
factors and treatment results were performed.
The mucositis intensity was high from 2nd to 5th week (the highest
mean - 15 Dische points in 4th week), but on acceptable level.
54.5% of CR of the tumor and 57.1% of nodes were noted. Survival
analysis showed 44% of a 2-year and 35% of a 4-year OS and 44%
of a 2-year and 38% of a 4-year survival excluding deaths from
distant metastases. Correlation between the hemoglobin level and
the nodal regression two months after the radiotherapy (p=0.01),
showed the tumor diameter and TCP (p=0.047), the OS and the nodes
diameter (p=0.004), the PS (p=0.02) and the hemoglobin level
(p=0.04).
CHA-CHA could be a valid method in advanced head and neck cancer
treatment but its efficacy should be confirmed in randomized phase
of trial.
Ako citovať:
ISO 690:
Miszczyk, L., Wozniak, G., Tarnawski, R., Maciejewski, B. 2005. Split-course accelerated hyperfractionation (CHA-CHA) for advanced
head and neck cancers - preliminary results. In NEOPLASMA, vol. 52, no.2, pp. 143-149. 0028-2685.
APA:
Miszczyk, L., Wozniak, G., Tarnawski, R., Maciejewski, B. (2005). Split-course accelerated hyperfractionation (CHA-CHA) for advanced
head and neck cancers - preliminary results. NEOPLASMA, 52(2), 143-149. 0028-2685.